Novartis AG (NOVN) Gets a Buy from Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of ...
Novartis downgraded to Neutral from Buy at UBS
UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes ...
InnovationRx: Federal Judges Halt Trump’s Cuts To NIH Research Payments
In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...
MM&M18h
Novartis buys back Anthos Therapeutics for up to $3.1B
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
PMLiVE20h
Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition
Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...
EuropaWire22h
Novartis Acquires Anthos Therapeutics to Advance Abelacimab in Stroke and Thrombosis Prevention
Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...
EuropaWire22h
Tag Archives: Phase 3 trials
Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 ...